Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial

• De-Shen Wang,
• Chao Ren,
• Shan-Shan Li,
• William Pat Fong,
• Xiao-Jun Wu,
• Jian Xiao,
• Bin-Kui Li,
• Yun Zheng,
• Pei-Rong Ding,
• Gong Chen,
• Miao-Zhen Qiu,
• Zhi-Qiang Wang,
• Feng-Hua Wang,
• Hui-Yan Luo,
• Feng Wang,
• Xiao-Zhong Wang,
• Ling-Yun Wang,
• De-Jin Xie,
• Tao Chen,
• Li-Ren Li,
• Zhen-Hai Lu,
• Xiao-Hui Zhai,
• Tian-Shu Liu,
• Ying Yuan,
• Jia-Qi Chen,
• Qiong Tan,
• Zhi-Zhong Pan,
• De-Sen Wan,
• Rong Zhang,
• Yun-Fei Yuan,
• Rui-Hua Xu,
• Yu-Hong Li

Affiliations

De-Shen Wang

Chao Ren

Shan-Shan Li

William Pat Fong

Xiao-Jun Wu

Jian Xiao

Bin-Kui Li

Yun Zheng

Pei-Rong Ding

Gong Chen

Miao-Zhen Qiu

Zhi-Qiang Wang

Feng-Hua Wang

Hui-Yan Luo

Feng Wang

Xiao-Zhong Wang

Ling-Yun Wang

De-Jin Xie

Tao Chen

Li-Ren Li

Zhen-Hai Lu

Xiao-Hui Zhai

Tian-Shu Liu

Ying Yuan

Jia-Qi Chen

Qiong Tan

Zhi-Zhong Pan

De-Sen Wan

Rong Zhang

Yun-Fei Yuan

Rui-Hua Xu

Yu-Hong Li